James E. Bradner

Molecular Biology · 2005–2018

A researcher in the Science corpus: 23 papers; trusts 16 researchers and is trusted by 6 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 410 citations into it; #6,621 of 17,773 by trust here, #810 by citations
• Oncology — 82 citations into it
• Hematology — 76 citations into it; #223 of 225 by trust here, #8 by citations
• Pulmonary and Respiratory Medicine — 32 citations into it
• Cell Biology — 9 citations into it

Whom James E. Bradner trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. I. Weinstein
2. Charles Y. Lin
3. Denes Hnisz
4. P. Rahl
5. Alexandros Stamatakis
6. L. Soucek
7. M. Kagey
8. C. Vakoc
9. William A. Flavahan
10. B. Abraham

Who trusts James E. Bradner overall

1. A. West
2. Ricky W. Johnstone

Papers from James E. Bradner's perspective

Ordered by how strongly the researchers James E. Bradner trusts endorse each paper. Same corpus, a different order for every researcher.

1. Model-based Analysis of ChIP-Seq (MACS)
2. Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC (Science)
3. Modelling Myc inhibition as a cancer therapy (Nature)
4. The metazoan Mediator co-activator complex as an integrative hub for transcriptional regulation (Nature reviews genetics)
5. The long-range interaction landscape of gene promoters (Nature)
6. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia (Nature)
7. Initial genome sequencing and analysis of multiple myeloma (Nature)
8. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. (Cell)
9. Enhancer function: new insights into the regulation of tissue-specific gene expression (Nature reviews genetics)
10. The Double Bromodomain-containing Chromatin Adaptor Brd4 and Transcriptional Regulation* (Journal of Biological Chemistry)

Their papers

• BET bromodomain inhibition as a therapeutic strategy to target c-Myc (2011) — 2,801 citations
• Selective inhibition of BET bromodomains (2010) — 4,002 citations
• Transcriptional Amplification in Tumor Cells with Elevated c-Myc (2012) — 1,502 citations
• Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers (2013) — 2,748 citations
• RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia (2011) — 1,853 citations
• Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies (2007) — 962 citations
• Discovery and Characterization of Super-Enhancer Associated Dependencies in Diffuse Large B-Cell Lymphoma (2013) — 694 citations
• Selective Target Protein Degradation via Phthalimide Conjugation (2015) — 1,045 citations
• Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset (2015) — 689 citations
• Transcriptional Addiction in Cancer (2017) — 1,026 citations
• HDAC2 negatively regulates memory formation and synaptic plasticity (2009) — 1,612 citations
• R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling (2017) — 977 citations
• Chemical Phylogenetics of Histone Deacetylases (2010) — 702 citations
• Targeting MYCN in neuroblastoma by BET bromodomain inhibition. (2013) — 628 citations
• The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins (2013) — 1,381 citations
• The dTAG system for immediate and target-specific protein degradation (2018) — 886 citations
• Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. (2005) — 610 citations
• YY1 Is a Structural Regulator of Enhancer-Promoter Loops (2017) — 886 citations
• PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. (2007) — 708 citations
• Plasticity in binding confers selectivity in ligand induced protein degradation (2018) — 492 citations